Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW)

LIU, S; LEE, S; LA CAVA, A; MOTRAN, CLAUDIA CRISTINA; HAHN, B; MICELI, MC

SAGE PUBLICATIONS LTD

Año: 2011 vol. 20 p. 473 - 473

ystemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by a hyperactive immune system, including activation of autoreactive T and B cells. These studies demonstrate that administration of recombinant galectin-1, a b-galactose binding protein, to SLE-prone (NZBNZW) F1 mice reduced lymphocyte activation, inhibited serum anti-double-stranded DNA(dsDNA) IgG antibody production, decreased the incidence of proteinuria, and increased survival rate. In addition, recombinant galectin-1?-treated mice had a higher frequency of Foxp3 expression, which suggested an increase in the percentage of peripheral regulatory T cells. Consistent with the finding that there were fewer activated T lymphocytes, ex vivo T cells from mice treated with recombinant galectin-1 exhibited less proliferation in response to TCR stimulation. Furthermore, these cells were less efficient at lipid raft clustering in response to TCR/CD28 engagement, consistent with published reports that